MRK - Merck & Company - Stock Price & Dividends

Merck & Co., Inc. is a global healthcare company that operates through two primary segments: Pharmaceutical and Animal Health. The Pharmaceutical segment focuses on developing and marketing human health products, including medicines and vaccines, to treat a range of conditions such as cancer, infectious diseases, and chronic conditions like diabetes and cardiovascular disease.

The company's Pharmaceutical segment offers a diverse portfolio of products, including Keytruda, a leading treatment for various types of cancer, as well as vaccines like Gardasil and Gardasil 9, which protect against certain types of human papillomavirus (HPV). Additionally, Merck & Co., Inc. markets products like Januvia, a medication for type 2 diabetes, and Simponi, a treatment for autoimmune disorders such as rheumatoid arthritis and psoriasis.

The Animal Health segment is dedicated to improving the health and well-being of animals through the development, manufacture, and marketing of veterinary pharmaceuticals, vaccines, and health management solutions. This segment also offers digitally connected identification, traceability, and monitoring products to help animal owners and veterinarians manage animal health more effectively.

Merck & Co., Inc. serves a wide range of customers, including drug wholesalers and retailers, hospitals, government agencies, managed health care providers, physicians, veterinarians, animal producers, farmers, and pet owners. The company has established partnerships with other pharmaceutical companies, such as AstraZeneca PLC, Daiichi Sankyo, Eisai Co., Ltd., Bayer AG, and Moderna, Inc., to co-develop and co-commercialize various products, including cancer treatments and vaccines.

One notable partnership is the collaboration with AstraZeneca PLC to co-develop and co-commercialize Lynparza, a treatment for certain types of cancer, and Koselugo, a medication for neurofibromatosis type 1. Additionally, Merck & Co., Inc. has a development and commercialization agreement with Daiichi Sankyo for three deruxtecan ADC candidates, which are being investigated as potential treatments for multiple solid tumors.

Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey. With a long history of innovation and a commitment to improving human and animal health, the company continues to be a leader in the global healthcare industry.